Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer.
作者信息
Korkes Fernando, Timóteo Frederico, Ferrari Karen Linares, Reis Leonardo Oliveira
机构信息
Divisão de Urologia, Faculdade de Medicina do ABC-FMABC, Santo André, SP, Brasil.
Hospital Israelita Albert Einstein, São Paulo, SP, Brasil.
出版信息
Int Braz J Urol. 2021 Mar-Apr;47(2):232-236. doi: 10.1590/S1677-5538.IBJU.2021.02.02.
Abstract
摘要
相似文献
1
Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer.卡介苗（BCG）在膀胱癌治疗中的巴西幕后故事
Int Braz J Urol. 2021 Mar-Apr;47(2):232-236. doi: 10.1590/S1677-5538.IBJU.2021.02.02.
2
The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.经膀胱内卡介苗治疗的非肌肉浸润性膀胱癌患者，再次经尿道电切术对复发率和进展率的影响。
J Urol. 2014 Feb;191(2):341-5. doi: 10.1016/j.juro.2013.08.022. Epub 2013 Aug 20.
3
Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.卡介苗膀胱内灌注治疗非肌层浸润性膀胱癌：综述
Int J Urol. 2018 Jan;25(1):18-24. doi: 10.1111/iju.13410. Epub 2017 Jul 25.
4
Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.卡介苗治疗失败后的高危非肌肉浸润性膀胱癌行膀胱内吉西他滨灌注治疗。
J Urol. 2013 Nov;190(5):1686-91. doi: 10.1016/j.juro.2013.04.120. Epub 2013 May 7.
5
Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.经尿道治疗非肌肉浸润性膀胱癌：系统评价和荟萃分析。
J Urol. 2017 May;197(5):1189-1199. doi: 10.1016/j.juro.2016.12.090. Epub 2016 Dec 24.
6
Bacillus Calmette-Guérin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal?卡介苗（BCG）无反应的非肌层浸润性膀胱癌：各亚组相同吗？
BJU Int. 2023 Oct;132(4):384-386. doi: 10.1111/bju.16087. Epub 2023 Jun 15.
7
Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment.卡介苗联合静脉注射派姆单抗治疗卡介苗治疗后复发或持续性高级别非肌层浸润性膀胱癌的 I 期临床试验。
World J Urol. 2021 Oct;39(10):3807-3813. doi: 10.1007/s00345-021-03716-3. Epub 2021 May 8.
8
T1 Substaging of Nonmuscle Invasive Bladder Cancer is Associated with bacillus Calmette-Guérin Failure and Improves Patient Stratification at Diagnosis.T1 非肌肉浸润性膀胱癌的亚分期与卡介苗治疗失败相关，并可改善诊断时的患者分层。
J Urol. 2021 Mar;205(3):701-708. doi: 10.1097/JU.0000000000001422. Epub 2020 Nov 16.
9
Predictive biomarkers of response to bacillus Calmette-Guérin immunotherapy and bacillus Calmette-Guérin failure for non-muscle invasive bladder cancer.预测卡介苗免疫治疗和卡介苗失败对非肌肉浸润性膀胱癌反应的生物标志物。
Int J Urol. 2022 Aug;29(8):807-815. doi: 10.1111/iju.14921. Epub 2022 May 22.
10
The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.经膀胱内吉西他滨联合 1/3 剂量卡介苗灌注治疗对非肌层浸润性膀胱癌患者生活质量的影响：一项前瞻性、随机、Ⅱ期临床试验的结果。
J Urol. 2013 Sep;190(3):857-62. doi: 10.1016/j.juro.2013.03.097. Epub 2013 Mar 29.
引用本文的文献
1
Intradermal priming to intravesical Bacillus Calmette-Guérin in non-muscle invasive bladder cancer: A translational research and phase I clinical trial.非肌层浸润性膀胱癌中卡介苗膀胱内灌注的皮内预充：一项转化研究和I期临床试验。
Oncol Res. 2025 May 29;33(6):1495-1503. doi: 10.32604/or.2025.061812. eCollection 2025.
2
Challenges and opportunities in NMIBC management across Latin America: insights from healthcare providers and a patient advocacy group.拉丁美洲非肌层浸润性膀胱癌管理中的挑战与机遇：来自医疗服务提供者和患者倡导组织的见解
Ecancermedicalscience. 2024 Jun 7;18:1711. doi: 10.3332/ecancer.2024.1711. eCollection 2024.
本文引用的文献
1
Increasing costs from bladder cancer in the Brazilian Health System: the role of establishing public health policies.巴西卫生系统中膀胱癌成本的不断增加：制定公共卫生政策的作用。
Int Braz J Urol. 2021 Mar-Apr;47(2):443-447. doi: 10.1590/S1677-5538.IBJU.2020.0658.
2
Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly.激活：卡介苗疫苗接种预防老年人感染的随机临床试验。
Cell. 2020 Oct 15;183(2):315-323.e9. doi: 10.1016/j.cell.2020.08.051. Epub 2020 Sep 1.
3
BCG-induced trained immunity: can it offer protection against COVID-19?BCG 诱导的训练免疫：能提供针对 COVID-19 的保护吗？
Nat Rev Immunol. 2020 Jun;20(6):335-337. doi: 10.1038/s41577-020-0337-y.
4
Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic?全球卡介苗接种诱导的训练免疫与SARS-CoV-2大流行的进展相关吗？
Allergy. 2020 Jul;75(7):1815-1819. doi: 10.1111/all.14345. Epub 2020 Jun 8.
5
Bladder cancer trends and mortality in the brazilian public health system.巴西公共卫生系统中的膀胱癌趋势和死亡率。
Int Braz J Urol. 2020 Mar-Apr;46(2):224-233. doi: 10.1590/S1677-5538.IBJU.2019.0198.
6
Targeting innate immunity for tuberculosis vaccination.针对结核病疫苗接种的固有免疫。
J Clin Invest. 2019 Sep 3;129(9):3482-3491. doi: 10.1172/JCI128877.
7
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.欧洲泌尿外科学会非肌肉浸润性膀胱癌（TaT1 和原位癌）指南 - 2019 年更新版。
Eur Urol. 2019 Nov;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20.
8
Non-specific effects of BCG vaccine on viral infections.卡介苗疫苗对病毒感染的非特异性作用。
Clin Microbiol Infect. 2019 Dec;25(12):1473-1478. doi: 10.1016/j.cmi.2019.04.020. Epub 2019 May 2.
9
Bacillus Calmette-Guérin (BCG) vaccine: A global assessment of demand and supply balance.卡介苗（BCG）疫苗：全球需求和供应平衡评估。
Vaccine. 2018 Jan 25;36(4):498-506. doi: 10.1016/j.vaccine.2017.12.010. Epub 2017 Dec 15.
10
Immunometabolic Pathways in BCG-Induced Trained Immunity.卡介苗诱导的训练性免疫中的免疫代谢途径
Cell Rep. 2016 Dec 6;17(10):2562-2571. doi: 10.1016/j.celrep.2016.11.011.
Zotero 插件